Introduction
Vernal keratoconjunctivitis (VKC) is a chronic, seasonally exacerbated bilateral external allergic ocular inflammation associated with remodelling of the conjunctiva. Characteristic features of conjunctival remodelling in VKC include hyperplasia of the epithelium with numerous epithelial ingrowths, and extensive deposition of extracellular matrix components, including types I, III, IV, V, and VII collagen, tenascin, and laminin in the substantia propria. [1] [2] [3] [4] In addition, angiogenesis, the growth and proliferation of new blood vessels, is one of the histological hallmarks of tissue remodelling of the allergic inflammation. 5 The mechanisms by which chronic conjunctival inflammation in VKC promotes conjunctival remodelling have not been clarified yet. Potential candidates are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF, also known as vascular permeability factor), transforming growth factor-b (TGFb), basic fibroblast growth factor (bFGF), and plateletderived growth factor (PDGF). EGFR, a member of the receptor tyrosine kinase family, plays a role in epithelial cell migration, proliferation and differentiation, and enhanced survival. 6, 7 VEGF plays a central role in the process of angiogenesis and increases vascular permeability so that plasma proteins can leak into the extravascular space, which leads to oedema and profound alterations in the extracellular matrix. [8] [9] [10] TGF-b is able to stimulate fibroblast proliferation and increase the synthesis by fibroblasts of many components of the extracellular matrix. 11 bFGF is a potent mitogen for many cell types including fibroblasts, and endothelial cells. 12 PDGF is a potent mitogen for fibroblasts. 13 Integrins are a family of heterodimeric cell surface receptors, which consist of a and b subunits. They mediate interactions of cells with different components of the extracellular matrix, and cell-cell interactions. 14 Integrin a3b1 interacts with laminin, fibronectin, and collagen, and integrin a6b1 is a receptor for laminin. 14 Integrin a6b4, which is expressed primarily on the basal surface of most epithelia, is defined as an adhesion receptor for most of the known basement membrane laminins. A primary function of a6b4 integrin is to maintain the integrity of epithelia. This critical role for a6b4 derives from its ability to mediate the formation of stable and rigid adhesive structures known as hemidesmosomes on the basal cell surface that link the cytokeratin filament network with laminins in the basement membrane. 15 Several studies have demonstrated the involvement of a3b1, a6b1, and a6b4 integrins in epithelial wound healing and in the migration of epithelial cells and epithelial-derived carcinoma cells. [16] [17] [18] [19] [20] In addition, several studies suggested that these integrins are essential participants in new vessel growth and remodelling. 21, 22 Recent studies have demonstrated that growth factors regulate the expression of a3b1, a6b1, and a6b4 integrins, modulate integrin-mediated cell adhesion and motility, and their receptors share proteins that mediate intracellular signalling with integrin receptors. [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] [29] The crosstalk between these receptors is thought to play a relevant role in the migration of epithelial cells and epithelial-derived carcinoma cells. 28 Collectively, these data suggest that both growth factors and a3b1, a6b1, and a6b4 integrins affect tissue remodelling.
On the basis of this, we hypothesized that EGFR, VEGF, TGF-b, bFGF, and PDGF and the integrins a3b1, a6b1, and a6b4 might play a role in the pathophysiology of VKC, especially in conjunctival remodelling. To examine this hypothesis, we studied, with immunohistochemical techniques, their expression in conjunctival biopsy specimens from patients with active VKC, and from normal individuals. In addition, we examined the expression of Ki67 antigen, which is a marker for cell proliferation. 30 
Materials and methods
A total of 16 consecutive patients with active VKC presenting to the outpatient clinic of King Abdulaziz University Hospital were included in this study. The patients were 11 males, and five females, with a mean age of 14.576.11 (range, 8-25 years). The symptoms in all patients included itching, redness, photophobia, and tearing. All patients had the limbal form of the disease characterized by broad gelatinous infiltrates of the limbus. A clinical score (0-4: 0 ¼ absent; 4 ¼ severe) was given considering the severity of the following eye symptoms and signs: itching, redness, photophobia, tearing, conjunctival erythema, conjunctival chemosis, discharge, limbal infiltrates, and corneal epithelial disease. All the patients had severely active VKC. A limbal conjunctival biopsy specimen was obtained from each patient. None of the patients was on topical or systemic therapy before the biopsy. In addition, nine limbal conjunctival biopsy specimens were obtained from patients undergoing strabismus surgery without obvious inflammation, who served as controls. The controls were from the same age group, and were five males, and four females. This study was approved by the Research Center, College of Medicine, King Saud University, the patients and controls were admitted to the study and their guardians gave informed consent.
Immunohistochemical staining
The conjunctival biopsy specimens were embedded in OCT (optimum cutting temperature compound, TissueTek, Miles Laboratories, IN, USA), immediately snap frozen in liquid nitrogen and maintained at À801C until use. For immunohistochemistry, 5 mm serially cut cryostat sections were fixed in absolute acetone for 10 min and then treated with 2% hydrogen peroxide in methanol for 3 min to block endogenous peroxidase activity. After rinsing three times in phosphate-buffered saline (PBS) at pH 7.2 for 15 min, the slides were incubated for 30 min with the monoclonal and polyclonal antibodies as listed in Table 1 . Three sections were stained per antibody for each patient. Optimal conditions and concentrations of all antibodies used were determined in pilot experiments, including staining of cryostat sections immediately after being prepared or following drying overnight at room temperature. After a wash with PBS, the sections were incubated for 30 min with EnVision þ , peroxidase, Rabbit, or EnVision þ , peroxidase, Mouse (DAKO, CA, USA). These are goat anti-rabbit or anti-mouse immunoglobulins conjugated to peroxidase labelled dextran polymer. The products react with rabbit immunoglobulins, or with mouse immunoglobulins of all classes and minimally with human immunoglobulins, thus allowing better visualization. The slides were washed again with PBS and the reaction product was visualized by incubation for 10 min in 0.05 M acetate buffer at pH 4.9, containing 0.05% 3-amino-9-ethylcarbazole (Sigma-Aldrich, Bornem, Belgium) and 0.01% hydrogen peroxide, resulting in bright-red immunoreactive sites. The slides were faintly counterstained with Harris haematoxylin. Finally, the sections were rinsed with distilled water and coverslipped with glycerol. Omission or substitution of the primary antibody with an irrelevant antibody of the same species, and staining with chromogen alone were used as negative controls. Normal oesophageal and skin biopsies as well as biopsies from oesophageal cancer and different forms of inflammatory bowel and skin diseases were used as positive controls.
Double Immunohistochemistry
To examine the phenotype of inflammatory cells expressing growth factors, cryostat sections were studied by sequential double immunohistochemistry. Colocalization studies were performed in VKC specimens from three patients. After rinsing the slides with PBS, they were incubated for 30 min with the first antibody and rinsed again with PBS. Subsequently, the sections were incubated for 30 min with EnVision þ , peroxidase, Mouse (DAKO, CA, USA) and washed again with PBS. The reaction product was visualized by incubation for 10 min in 0.05 M acetate buffer at 4.9, containing 3-amino-9-ethyl-carbazole 0.05% (Sigma-Aldrich, Bornem, Belgium) and hydrogen peroxide 0.01%, resulting in red immunoreactive staining. Subsequently, the sections were rinsed in acetate buffer, washed with tap water, rinsed in PBS and incubated for 30 min with the second antibody. After a wash with PBS, the sections were incubated for 30 min with EnVision þ , alkaline phosphatase, Rabbit (DAKO, CA, USA). The blue reaction product was developed using 5-bromo-4-chloro-3-indoxyl phosphate and nitro blue tetrazolium chloride (BCIP/NBT) (DAKO, CA, USA) for 30 min. No counterstain was applied.
Quantitation
Inflammatory mononuclear cells showing immunoreactivity were counted in five representative fields. Only cells containing a clearly identifiable nucleus were counted. Counting was performed by two independent observers (AMA and KG). One of them (KG) was unaware of the origin of the specimens. In case of disagreement, the results obtained by the blinded observer were used. We used an eyepiece calibrated grid with Â 40 magnification. With this magnification and calibration, we counted the cells present in an area of 0.33 Â 0.22 mm. For the colocalization studies, inflammatory cells expressing both growth factors and eosinophil peroxidase, or CD68 were counted and expressed as a percentage of cells expressing growth factors.
Statistical analysis
All data are presented as mean7SD. The data were analysed using the Kruskal-Wallis nonparametric test for one-way analysis of variance (ANOVA). Program 3 S from the BMDP Statistical Package was used to conduct the ANOVA. Post-ANOVA pairwise comparisons were based on the Z-test.
Results
There was no staining in the negative control slides, and when the chromogen alone was applied.
Integrins: In normal conjunctiva, very weak immunoreactivity for the integrin a3 subunit was localized at the cell membranes of the basal epithelial cells, and on vascular endothelial cells in the upper substantia propria (Figure 1 ). Very weak membranous immunoreactivity for the integrin a6 subunit was observed at the basal aspect of the basal epithelial cells, and on vascular endothelial cells in the upper substantia propria (Figure 2 ).
In all VKC specimens, strong membranous immunoreactivity for the integrin a3 ( Figure 3 ) and a6 ( Figure 4 ) subunits was observed on the basal and suprabasal epithelial cells, except the most superficial cells. The staining pattern of the integrin a6 subunit at the basal aspect of the basal epithelial cells appeared as a
Ki67 antigen: MIB-1 staining was negative in the normal conjunctiva. All VKC specimens showed nuclear immunoreactivity for MIB-1 in the basal and suprabasal epithelial cells ( Figure 5 ). Growth factors: In normal conjunctiva, there was very weak cytoplasmic immunoreactivity for VEGF and EGFR in the epithelium. There was no immunoreactivity for TGF-b, bFGF, and PDGF.
All VKC specimens showed strong membranous and cytoplasmic immunoreactivity for EGFR ( Figure 6 ) and VEGF ( Figure 7 ) in the epithelium. Immunoreactivity for VEGF was observed in all epithelial layers and was more intense in the deeper layers, whereas immunoreactivity for EGFR was observed only in the deeper layers. Inflammatory cells expressing pronounced cytoplasmic VEGF, EGFR, TGF-b (Figure 8) , bFGF, and PDGF were noted in the substantia propria. The immunohistochemical appearance of these inflammatory cells was similar for all the growth factors studied. EGFR þ inflammatory cells were observed in eight specimens, VEGF þ inflammatory cells were observed in nine specimens, TGF-b þ inflammatory cells were observed in 11 specimens, bFGF þ inflammatory cells were observed in 10 specimens, and PDGF þ inflammatory cells were observed in 10 specimens. The cell counts are presented in Table 2 . The mean values of the five groups did not differ significantly (P ¼ 0.6920, ANOVA). Double immunohistochemistry to confirm the phenotype of TGF-b-positive inflammatory cells showed that most inflammatory cells expressing TGF-b were eosinophils (mean7SD, 4574%, N ¼ 3) (Figure 9 ) and monocytes/macrophages (mean7SD, 3574%, N ¼ 3).
Discussion
In normal conjunctiva, expression of epithelial integrin a3 and a6 subunits was weak, and largely confined to the basal layer. The integrin a6 subunit was expressed at the basal aspect of the basal epithelial cells, whereas the integrin a3 subunit was expressed at the cell membrane of the basal epithelial cells. Our observations are consistent with reports that a3, a6, b1, and b4 integrin subunits were expressed only on the basal layer of proliferating keratinocytes in normal skin, 16, [31] [32] [33] [34] and on the basal epithelial cells in normal cornea. [35] [36] [37] In fact, the integrin a6 subunit (CD49f) is known to be associated with hemidesmosomes of basal keratinocytes. 32 Compared to normal conjunctiva, the conjunctiva from patients with active VKC showed strong expression of the integrin a3 and a6 subunits on the basal and suprabasal epithelial cells. Similarly, aberrant expression of integrins on suprabasal keratinocytes has been observed in hyperproliferative epidermis in wound repair, 16, 31, 33 and psoriasis. 33, 38 In addition, suprabasal integrin expression is seen in response to corneal epithelial injury, 39 after anterior keratectomy, 35 in keratoconus cornea, 36 and in superior limbic keratoconjunctivitis. 40 Carroll et al 41 demonstrated that suprabasal integrin expression in transgenic mice is a cause of abnormal keratinocyte behaviour including epidermal hyperproliferation and skin inflammation.
Taken together, these reports suggest that suprabasal expression of integrins, and expression of a6b4 integrin at nonhemidesmosomal sites in epithelial tissues is associated with changes in cell proliferative capability toward a high potential for proliferation. The occurrence of Ki67-positive cells in the basal and suprabasal layers of the conjunctival epithelium in VKC supports this hypothesis. Upregulation of epithelial integrins in VKC is to be expected because of the function of these molecules in epithelial wound healing. During wound healing, migrating keratinocytes express a3b1, a6b1, and a6b4 integrins, 16 and migrating corneal epithelial cells express a6b4 integrin. 20 Lotz et al 17 demonstrated that the a3b1, a6b1, and a6b4 integrins mediate epithelial cell migration that is requisite for resealing of disruptions in the mucosal lining of the gastrointestinal tract. Pouliot et al 19 demonstrated a critical role for a3b1 and a6b4 integrin receptors in laminin-10-mediated migration of colon cancer cells. In a previous report, 4 we showed immunoreactivity for laminin among the basal epithelial cells in VKC suggesting that this pathway is also mediating epithelial remodelling in VKC. The integrin a6b4 also has a significant impact on signalling molecules that stimulate migration and invasion. 15 In the normal conjunctiva, vascular endothelial cells showed very weak immunoreactivity for the integrin a3 and a6 subunits. In contrast, the conjunctiva from patients with active VKC showed strong expression of these integrins on vascular endothelial cells. Our results are in agreement with those of others, who have also observed that microvascular endothelial cells express at their surface a3b1, a6b1, and a6b4 integrins. 22 Members of the integrin family of adhesion receptors are essential participants in blood vessel growth and remodelling. 21, 22 Enenstein et al 21 demonstrated in neonatal foreskin that a6b4 integrin was consistently found along the capillary loops and the distal ends of presumed sprouts, suggesting an important role for the a6b4 integrin in new vessel growth. Kelin et al 22 showed that bFGF-stimulated microvascular endothelial cells expressed increased levels of a3b1, a6b1, and a6b4 integrins and adhered better to laminin. In a previous study, 4 we demonstrated intense immunoreactivity for laminin, the ligand for a3b1, a6b1, and a6b4 integrins, 14, 15 around stromal vessels in VKC. Similarly, studies of induced angiogenesis in corneas have detected laminin at the tips of newly forming vessels. 42 Collectively, these data suggest that the interaction between the upregulated integrin receptors on endothelial cells and laminin might participate in the process of angiogenesis in VKC conjunctiva.
In the present study, EGFR immunoreactivity was strongly expressed in the deeper layers of the conjunctival epithelium in VKC. Similarly, several studies showed EGFR upregulation in the epithelium of asthmatic airways at both mRNA and protein levels. 6, 43, 44 In addition, in vitro studies showed that epidermal growth factor (EGF), and EGFR may play an important role in bronchial epithelial repair in asthma. EGFRselective inhibition was found to inhibit both EGFstimulated and basal wound closure. 6 It is possible that the strong expression of EGFR in the conjunctival epithelium in VKC may reflect the repair of damage incurred by the chronic inflammation. However, overhealing of the damage might be one of the mechanisms of conjunctival epithelial remodelling in VKC.
The results of the present study demonstrate that the expression of VEGF was upregulated in the conjunctiva of VKC patients compared with that of control subjects. Epithelial cells and inflammatory cells including eosinophils and monocytes/macrophages were the major cellular sources of VEGF. Our observations are in agreement with previous studies in asthma showing increased immunoreactivity for VEGF in the airways of asthmatic subjects that was expressed by eosinophils and macrophages. 5 Moreover, there was a significant correlation between the increased vascularity of the bronchial mucosa and the numbers of VEGF-positive cells. 5 Recently, Anthony et al 45 demonstrated that antigenic stimulation induces VEGF release in bronchial airway epithelial cells. In addition, a recent study reported overexpression of VEGF in a murine model of asthma, and inhibition of VEGF almost completely prevented the pathophysiological changes of asthma. 46 In the present study, the expression of the fibrogenic growth factors TGF-b, bFGF, and PDGF was increased in VKC conjunctiva compared with expression in normal conjunctiva. Our data are in agreement with those of Leonardi et al 3 for inflammatory cells. Eosinophils and monocytes/macrophages were the major cellular sources of TGF-b, bFGF, and PDGF. However, in our study, TGFb, PDGF, and bFGF were not expressed by the conjunctival epithelium, endothelial cells, and extracellular conjunctival stroma. This difference can be explained by differences in the antibodies used. Growth factors can modulate the level of expression and function of integrins in several cell types. TGF-b enhances the expression of a3b1 integrin by epithelial cells, 24, 25 and fibroblasts, 23 and a6b1 integrin by epithelial cells. 29 bFGF stimulation of endothelial cells induces an increase in a3b1, a6b1, and a6b4 integrin expression. 22 EGF increases a3b1 integrin expression in epithelial cells, 25 and a6b4 integrin expression in epithelial cells, 20 and cancer cells. 19 The results from integrin inhibition experiments indicate that migration of EGF-stimulated cancer cells on laminin-10 is mediated by both a3b1 and a6b4 integrins. 19 Robinovitz et al 18 demonstrated that EGF-stimulated chemotaxis of squamous carcinoma cells on laminin-1 was associated with mobilization of a6b4 integrin from hemidesmosomes and their redistribution to actin-rich protrusions. Several studies examined the mechanisms that induce disassembly of hemidesmosomes and inactivation of the ability of a6b4 integrin to mediate stable adhesion to basement membrane during epithelial migration. It was demonstrated that EGFR combines with the hemidesmosomal integrin a6b4 and that activation of the EGFR causes tyrosine phosphorylation of the b4 cytoplasmic domain and disruption of hemidesmosomes. 18, 26 The interaction between growth factors and cell integrin receptors was also highlighted by Falcioni et al, 28 who demonstrated that a6b1 and a6b4 integrins are associated with tyrosine kinase receptors in tumour cells. Tumour cells overexpressing both receptors showed enhanced proliferation rates. 28 In agreement with these data, the deeper layers of conjunctival epithelium in VKC coexpressed both EGFR and integrin receptors that might enhance the hyperproliferative capability of these cells. In addition, integrins can regulate growth factor expression. Recently, Chung et al 27 demonstrated that a6b4 integrin can enhance VEGF translation in carcinoma cells.
In conclusion, we have demonstrated significant overexpression of a3 and a6 integrin subunits, EGFR, VEGF, TGF-b, bFGF, PDGF, and Ki67 antigen in VKC lesions. These results suggest a possible contribution of integrins, EGFR, and growth factors in mediating conjunctival remodelling in VKC. Further in vitro studies on the interactions between integrins, growth factors, growth factor receptors, and components of the extracellular matrix may elucidate the pathophysiology of conjunctival remodelling that characterizes VKC.
